title: [The effect of chemotherapy on survival time in advanced breast carcinoma].
abstract: Survival time of 119 consecutive patients with metastasizing carcinoma of the breast who had been treated with various chemotherapeutic schedules after radical operation was determined retrospectively. 57 women received chemotherapy and hormones, as well as radiotherapy, while 62 had radiotherapy plus hormone treatment. The mean prolongation of life in the former group over that of the latter was 12 months (P less than 0.01). Although chemotherapy delayed death, the dynamics of the cancer were not fundamentally affected. The chemotherapy-induced prolongation (2.5 months--five years) was independent of any extra risk, primary location of the metastases or age.
authors.affiliation: Radiologische Klinik des Katharinenhospitals Stuttgart.
authors.forename: H D
authors.initials: HD
authors.lastname: Schoen
authors.forename: T
authors.initials: T
authors.lastname: Wendt
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality*; D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D009362:Neoplasm Metastasis; D011182:Postoperative Care; D011241:Prednisone / Q000008:administration & dosage; D012189:Retrospective Studies; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D002330:Carmustine; D011241:Prednisone
vernacular_title: Wirkung der Chemotherapie auf die Uberlebenszeit bei fortgeschrittenem Mammakarzinom.